One size doesn’t necessarily fit all when it comes to testing the effects, including cancer and other diseases, of endocrine-disrupting chemicals (EDC) or toxins, which target many factors, including the estrogen receptor (ER). Most current screening uses high throughput assays that only focus on bulk population analysis and/or engineered systems without taking into account phenotypic heterogeneity or cell-to cell-variability of endogenous receptors. Researchers at Baylor College of Medicine have now developed a two-tiered image analysis-based quality control pipeline that exploits single cell variations in evaluating chemical effects.
Click here for original story, Team develops quality control for single cell imaging
Source: Phys.org